Fig. 6: Treatment with OT-82 does not affect longevity or biological age of mice. | Leukemia

Fig. 6: Treatment with OT-82 does not affect longevity or biological age of mice.

From: OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis

Fig. 6

a Kaplan–Meier survival curves for male (left panel, n = 19) and female (right panel, n = 19) NIH Swiss mice treated at the indicated times with four cycles of OT-82 or vehicle. Each cycle consisted of 2 consecutive weeks of treatment (3 days of daily PO administration of 30 mg/kg OT-82 or vehicle followed by 4 days with no treatment); cycles were separated by 2 weeks with no treatment. The first treatment cycle was started when mice were 87 weeks old. Physiological Frailty Index (PFI) was measured 1 week after the last treatment (at 102 weeks chronological age). b Average Physiological Frailty Index values in the groups of mice described in a as determined 1 week after the last treatment; p values are shown for comparison of vehicle- and OT-82-treated groups of each gender (two-tailored Student’s t test). Error bars indicate SEM. c Comparison of projected “biological ages” of mice from OT-82-treated and vehicle-treated groups calculated based on their PFIs.

Back to article page